Kerbauy Gilselena, Vivan Ana C P, Simões Glenda C, Simionato Ane S, Pelisson Marsileni, Vespero Eliana C, Costa Silvia F, Andrade Celia G T de J, Barbieri Daiane M, Mello João C P, Morey Alexandre T, Yamauchi Lucy M, Yamada-Ogatta Sueli F, de Oliveira Admilton G, Andrade Galdino
Department of Microbiology, Londrina State University, CEP: 86051-990, Londrina, Brazil.
Curr Pharm Biotechnol. 2016;17(4):389-97. doi: 10.2174/138920101704160215171649.
Multidrug-resistant organisms (MDRO) are a great problem in hospitals, where thousands of people are infected daily, with the occurrence of high mortality rates, especially in infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-producing Kpn). The challenge is to find new compounds that can control KPC producing-Kpn infections. The aim of this study was to evaluate the antibiotic activity of the F3d fraction produced by the Pseudomonas aeruginosa LV strain against clinical isolates of KPC-producing Kpn. The results showed that the minimum inhibitory concentration of F3d (62.5 µg mL(-1)), containing an organic metallic compound, killed planktonic cells of KPC-producing Kpn strains after 30 min of incubation. At the same concentration, this fraction also showed an inhibitory effect against biofilm of these bacteria after 24 h of incubation. Treatment with the F3d fraction caused pronounced morphological alterations in both planktonic and biofilm cells of the bacteria. The inhibitory effect of the F3d fraction seems to be more selective for the bacteria than the host cells, indicating its potential in the development of new drugs for the treatment of infections caused by KPC-producing Kpn and other MDRO.
多重耐药菌（MDRO）是医院面临的一个重大问题，每天都有数千人受到感染，死亡率很高，尤其是由产碳青霉烯酶肺炎克雷伯菌（产KPC的肺炎克雷伯菌，KPC-producing Kpn）引起的感染。面临的挑战是找到能够控制产KPC肺炎克雷伯菌感染的新化合物。本研究的目的是评估铜绿假单胞菌LV菌株产生的F3d组分对产KPC肺炎克雷伯菌临床分离株的抗菌活性。结果表明，含有有机金属化合物的F3d的最低抑菌浓度（62.5 µg mL(-1)）在孵育30分钟后可杀死产KPC肺炎克雷伯菌菌株的浮游细胞。在相同浓度下，该组分在孵育24小时后对这些细菌的生物膜也显示出抑制作用。用F3d组分处理导致细菌的浮游细胞和生物膜细胞均出现明显的形态改变。F3d组分的抑制作用对细菌似乎比对宿主细胞更具选择性，表明其在开发用于治疗产KPC肺炎克雷伯菌和其他多重耐药菌引起的感染的新药方面具有潜力。
